Search Results (302)

Hybrid magnetic–plasmonic nanoparticles offer a promising platform for cancer therapy by combining localized photothermal heating with nanoscale mechanical stimulation under remote laser irradiation and low-frequency alternating magnetic fields. However, the therapeutic potential of combining these effects remains insufficiently explored. In this study, we investigated the individual and combined effects of photothermal therapy (PTT) and magnetomechanical therapy (MMT) on the viability of Huh7 hepatocarcinoma cells in vitro using two types of layered Au–Fe microdisks (~1000 nm in diameter) with different layer sequences, i.e., Au(10)/Fe(70)/Au(10) (AFA) and Fe(50)/Au(10)/Fe(50) (FAF), where the values in parentheses denote the layer thicknesses in nanometers. The photothermal conversion efficiencies of the AFA and FAF microdisks in agarose were 35% and 53%, respectively, exceeding the values measured in aqueous solutions. After 24 h of incubation, both types of microdisks exhibited low intrinsic cytotoxicity up to concentrations of 100 µg/mL, at which the cell viability was reduced by no more than 7%. Application of either PTT or MMT enhanced cytotoxicity for both microdisk types. PTT was more effective for AFA microdisks, resulting in 29% cell death, whereas MMT showed greater efficacy for FAF microdisks, inducing 17% cell death. Notably, simultaneous PTT and MMT produced the strongest and synergistic therapeutic effect, leading to approximately 50% cell death. These findings demonstrate the potential of hybrid Au–Fe microdisks as multifunctional agents for combined photothermal and magnetomechanical cancer therapy. Full article

The kidney is an essential organ that has a crucial role in preserving homeostasis within the human body. Kidney cancer is considered a major clinical challenge owing to its resistance to traditional treatments such as chemotherapy, radiotherapy, and immunotherapy. Nanoparticles (NPs) gain great attention in cancer therapy due to their low toxicity, biocompatibility, and targeted drug delivery capability. This review focuses on the current role of green-synthesized NPs in renal cell carcinoma management and their applications in targeted drug delivery and cancer-specific targeting mechanisms with the demonstration of the environmentally friendly green synthesis approaches utilizing biological resources such as plant extracts and microorganisms, highlighting their advantages over conventional synthesis methods in terms of biocompatibility, sustainability, and reduced toxicity. Moreover, the therapeutic potential of nanomaterials is discussed, including magnetic NP-mediated thermal therapy, photothermal therapy, gene delivery systems, and RNA interference-based strategies. We underscore the challenges and limitations of NPs, including in vivo toxicity, biodistribution, clinical translation, large-scale production, batch-to-batch variability, long-term safety, scalability, repeatability, regulation, and reproducibility. There is growing potential to improve the treatment of kidney cancer. Hence, the promising prospects of nanotechnology in kidney cancer treatment provide a foundation for future research and clinical application. This comprehensive article highlights the significant contributions of nanomedicine to oncology and shows an optimistic perspective for more effective and precise treatment strategies for kidney cancer. Full article

Breast cancer treatment still faces challenges including local recurrence, systemic toxicity, tumor heterogeneity, drug resistance, and immunosuppression. Conventional systemic administration provides limited exposure at the tumor site and exhibits significant toxicity. Injectable hydrogels, combining the properties of minimally invasive administration, in situ gelation, local retention, and sustained release, have become a key platform for local precision drug delivery. Compared with nanomedicines or free drugs, hydrogels can both prolong drug retention time and achieve on-demand release through the modulation of crosslinking density, degradation rate, and responsive chemical bonds. This review is organized around the material logic of such systems. Injectable hydrogels are first classified into natural, synthetic, hybrid, supramolecular, nanocomposite, and self-healing systems, the in situ gelation chemistries available to each are compared, and network parameters such as crosslinking density, mesh size, swelling, porosity, modulus, and rheology are related to release kinetics and intratumoral retention. Current research is primarily advancing along two directions: one is the construction of pH-, enzyme-, redox/ROS-, hypoxia-, ATP-, glucose-or thermo-responsive hydrogels; the other is achieving active targeting by integrating functionalized hydrogels with targets such as CD44, folate receptor, integrins, EGFR, transferrin receptor, and HER2 or with biomimetic cell-membrane coatings. On this basis, hydrogels have been extended to cancer vaccines, immune checkpoint modulation, local delivery of CAR-T/CAR-NK, as well as combination therapies involving chemotherapy, photothermal therapy, photodynamic therapy, chemodynamic therapy, sonodynamic therapy, radiosensitization, gene therapy, and theranostics. The constraints imposed on hydrogel design by different payload classes, including small molecules, natural products, proteins and peptides, nucleic acids, antibodies, exosomes, and gene-editing machinery, are further examined, and imaging-integrated theranostic gels are discussed together with the emerging role of machine learning and digital fabrication in hydrogel optimization. Based on the biological foundations of breast cancer, this review summarizes advances in the material design, microenvironment-responsive release, targeting strategies, immunomodulation, and combination therapy of hydrogels, critically evaluates the limitations of each strategy, and aims to provide a reference for the design of mechanistically well-defined and translatable hydrogel delivery systems for breast cancer. Full article

Graphene oxide (GO), a functionalized derivative of graphene, has emerged as one of the most promising nanomaterials for biomedical applications owing to its unique physicochemical properties, including a large specific surface area, abundant oxygen-containing functional groups, excellent dispersibility, and versatile surface chemistry. This review provides a comprehensive overview of the progress made between 2005 and 2025 in the development and application of GO-based nanomaterials across diverse biomedical fields, including drug and gene delivery, cancer therapy, tissue engineering, antimicrobial treatment, bioimaging, and biosensing. Recent studies demonstrate that GO serves as an effective platform for the delivery of therapeutic agents, enabling targeted delivery, controlled release, and enhanced cellular uptake. Functionalized GO systems have also shown considerable potential in gene delivery and cancer treatment, particularly in combined therapeutic approaches involving chemotherapy and photothermal therapy. Furthermore, GO-based composites have been widely explored in tissue engineering due to their ability to support cell growth, proliferation, and tissue regeneration. In antimicrobial applications, GO exhibits promising activity against a broad range of microorganisms through multiple mechanisms, while its optical and magnetic properties have facilitated advancements in multimodal bioimaging and biosensing technologies. Despite these significant advances, challenges remain regarding the clinical translation of GO-based nanomaterials. Variations in synthesis methods, physicochemical properties, and surface modifications contribute to differences in biological responses, including biocompatibility and toxicity. The long-term safety, environmental impact, and lack of standardized evaluation protocols continue to be major concerns. Overall, graphene oxide represents a versatile and multifunctional nanomaterial with substantial potential for next-generation biomedical applications; however, further studies are required to establish standardized fabrication methods, comprehensive safety assessments, and clinically relevant performance evaluations. Full article

Background: Triple-negative breast cancer (TNBC), devoid of actionable targets for endocrine or HER2-directed therapy, is highly aggressive with elevated risks of recurrence and metastasis; surgical resection remains the mainstay of treatment, and postoperative chemotherapy serves as a key adjuvant modality for controlling residual disease. Doxorubicin (DOX), although widely used, shows limited tumor selectivity, considerable systemic toxicity, and poor control over drug release at the tumor site. To address these issues, we developed near-infrared (NIR)-responsive gold-decorated phase-change nanodroplets (AuNPs-DOX-NDs) that combine photothermal conversion, liquid-to-gas phase transition, and controlled DOX release in a single platform. Methods: The nanodroplets consisted of a perfluorohexane (PFH) core, a DOX-loaded lipid shell, and polyethyleneimine-modified gold nanoparticles (PEI-AuNPs) conjugated to the surface as the NIR photothermal component. Physicochemical characterization was performed to evaluate morphology, colloidal dispersity, and storage stability. Under 808 nm laser irradiation, the photothermal behavior, PFH vaporization, and DOX release properties of AuNPs-DOX-NDs were investigated. In vitro studies using 4T1 TNBC cells were conducted to assess intracellular DOX accumulation, cell proliferation, migration, and apoptosis. Results: Physicochemical characterization showed that the nanodroplets had a uniform nanoscale morphology, good colloidal dispersity, and acceptable storage stability. Under 808 nm laser irradiation, AuNPs-DOX-NDs exhibited concentration-dependent photothermal heating, which induced PFH vaporization and accelerated DOX release, indicating a clear stimulus-responsive release behavior. In vitro studies using 4T1 TNBC cells showed enhanced intracellular DOX accumulation after treatment with AuNPs-DOX-NDs. Upon laser irradiation, the nanodroplets further inhibited cell proliferation and migration and promoted apoptosis, suggesting an enhanced combined photothermal–chemotherapeutic effect in 4T1 TNBC cells. Conclusions: These results indicate that AuNPs-DOX-NDs may serve as a useful NIR-responsive platform for externally controlled drug release and enhanced combined photothermal-chemotherapy, and deserve further evaluation in vivo. Full article

Hollow mesoporous silica nanoparticles (HSNs) were synthesized via the Stöber method using resorcinol–formaldehyde resin as a template and further developed as a multifunctional nanocarrier for synergistic chemo–photothermal therapy. Docetaxel (DTX) and indocyanine green (ICG) were co-loaded into HSNs as the prodrug and photothermal agent. The loading sequence of these agents can critically affect encapsulation efficiency. Preloading DTX followed by ICG incorporation achieved the highest drug loading (38.65%) and preserved the photoactivity of ICG. The resulting ICG&DTX@NH₂-HSNs exhibited strong and stable near-infrared photothermal conversion, as well as pH- and laser-responsive drug release behavior. In vitro studies confirmed efficient cellular uptake by 4T1 tumor cells and enhanced cytotoxicity compared with single treatments. In vivo experiments demonstrated significant tumor growth suppression in 4T1 tumor-bearing mice, with the greatest effect observed under combined ICG&DTX@NH₂-HSNs and laser irradiation. Importantly, histological analysis of major organs revealed no obvious toxicity, confirming the biosafety of the present nanoplatform. This study confirmed the potential of hollow mesoporous silica-based nanocarriers as safe and effective platforms for combined chemotherapy and photothermal cancer therapy. Full article

Donor–acceptor (D–A) molecular systems are gaining increasing attention in cancer imaging and phototherapy due to their tunable optical properties and high photosensitizing efficiency. Encapsulation of such D–A molecules in nano-sized polymeric carriers can enhance the efficiency of antitumor therapy by passive tumor accumulation and controlled drug release. Here, we synthesized two D–A molecules—TTDCV and TTInd—based on triphenylamine with thiophene π-spacers and electron-withdrawing dicyanovinyl or indene-1,3-dione moieties. These molecules were used to preparate nanoparticles (NPs) via nanoprecipitation with amphiphilic polymers—poly(ethylene glycol)-block polylactide methyl ether (PEG-b-PLA) and polyethylene oxide-polypropylene oxide (PEO-PPO-PEO, Pluronic^® F-127). The resulting NPs had spherical morphology, core–shell structure and a tunable mean size (66–139 nm), depending on the polymer type used. Photothermal and photodynamic properties of the NPs were confirmed by intracellular reactive oxygen species generation and efficient heating even under 530 nm low dose irradiation (1 J/cm²), leading to substantial in vitro cytotoxicity against Sk-Br-3 and MCF-7 human breast cancer cells. Pluronic-encapsulated systems showed the strongest effect, reducing IC₅₀ values down to 0.99 µg/mL and achieving phototoxicity indices up to 22, accompanied by increased intracellular accumulation studied by confocal microscopy and flow cytometry. This study establishes relationships between molecular design, encapsulation approaches, and the biological performance of nanoparticles, enabling the rational engineering of D–A-derived nanotherapeutics for precision cancer treatment. Full article

The photothermal conversion capability of polydopamine (PDA) was exploited to load the anticancer drug doxorubicin (DOX) onto its surface via π-π stacking and hydrogen-bond interactions, yielding a PDA-DOX complex. In this study, biocompatible poly-L-lactic acid (PLLA) was employed as a shell material to fabricate multifunctional PLLA composite PDA-DOX (PLLA@PDA-DOX) nanobubbles with integrated functions of ultrasound imaging, photothermal therapy, and chemotherapy. The fabricated nanobubbles exhibited a uniform mean diameter of 489.30 ± 6.96 nm with a Polydispersity index (PDI) of 0.226 ± 0.01 and a DOX loading efficiency of 3.27%. Acute toxicity evaluation in mice revealed that the maximum tolerated dose of PLLA@PDA-DOX nanobubbles was markedly higher than the clinical equivalent dose, showing no detectable toxicity or allergic reactions. Under near-infrared (NIR) laser irradiation, the inhibition rate of HCCLM3 cells increased from 50.1% to 64.45%, indicating enhanced therapeutic efficacy through the combined effects of photothermal therapy and chemotherapy. Moreover, compared with the free DOX group, the survival rate of LX-2 cells in the composite nanobubble group significantly increased from 18.9 ± 1.56% to 68.8 ± 3.08%, suggesting that the PLLA@PDA-DOX nanobubbles effectively reduced the direct cytotoxicity of DOX by preventing its immediate contact with cells. Collectively, the results confirm that PLLA@PDA-DOX nanobubbles possess excellent biocompatibility, robust ultrasound imaging performance, and enhanced antitumor efficacy under NIR irradiation. This multifunctional nanosystem demonstrates promising potential as an integrated platform for simultaneous cancer diagnosis and therapy. Full article

Background and Objectives: Pancreatic cancer is highly metastatic, and metastasis is the main cause of cancer-related deaths. Therefore, finding methods to inhibit pancreatic cancer metastasis has important clinical value. Methods: N-dihydrogalactochitosan (GC) is an immunostimulant that can enhance the anti-tumor immune response to inhibit metastasis in combination with photothermal therapy. Results: Here, we found that GC can inhibit the migration of pancreatic cancer cells through interactions with caveolin-1 (Cav-1). The fluorescence of GC-FITC on the cell surface overlaps with Cav-1-Red, is enhanced by adCav-1, and is weakened by siCav-1, indicating that the localization of GC depends on Cav-1. GC inhibits the migration of malignant cells by blocking the signal transduction of Cav-1 and its downstream molecules. In an orthotopic pancreatic tumor model, GC can inhibit tumor metastasis in tumor-bearing mice. Conclusions: These results demonstrate GC’s capacity to act as a partner in pancreatic cancer therapy and indicate future directions for metastatic cancer therapy. Full article

Iron oxide nanoparticles have emerged as multifunctional compounds with prominent potential in cancer theranostics, particularly in photothermal therapy (PTT) and photodynamic therapy (PDT). Their unique electronic and crystal structures, such as the dispersion of Fe²⁺ and Fe³⁺ ions and d-orbital splitting, contribute to their magnetic and catalytic properties. In PTT, Fe₃O₄ nanoparticles exhibit moderate near-infrared (NIR) absorption and photothermal conversion efficiency, which can be enhanced through adjustments in particle size, surface modification, and combinations with other components. In PDT, Fe₃O₄ nanoparticles demonstrate intrinsic peroxidase-like catalytic activity, facilitating Fenton and photo-Fenton reactions that generate reactive oxygen species (ROS), including hydroxyl radicals (^•OH), thereby amplifying oxidative stress in cancer cells. These nanoparticles can also function as carriers for photosensitisers (PS), promoting targeted delivery and enhanced ROS generation. Multifunctional nanomaterials that integrate Fe₃O₄ with other therapeutic agents and targeting ligands have demonstrated synergistic antitumour effects through amplified photothermal, photodynamic, chemodynamic, and chemotherapeutic mechanisms. Despite certain drawbacks, such as relatively low NIR absorption and challenges in optimising delivery and light activation, ongoing improvements in Fe₃O₄-based nanoplatforms present significant potential for enhancing treatment outcomes and the precision of cancer therapy. This article systematically explores the synergistic role of Fe₃O₄ nanoparticles in PTT and PDT, encompassing their magnetic and catalytic characteristics. Additionally, it focuses on multifunctional hybrid nanoplatforms that combine Fe₃O₄ with targeting or imaging agents, highlighting their potential to enhance therapeutic precision. Full article

Objectives: To fabricate polysialic acid (PSA)-modified liposomes co-loaded with doxorubicin (DOX) and indocyanine green (ICG) for synergistic chemotherapy and photothermal therapy, and to enhance the anti-cervical cancer efficacy of liposomes via neutrophil targeting. Methods: PSA-DOX/ICG liposomes (PSA-DOX/ICG-Lip) were prepared by microfluidic technology. The physicochemical properties, including drug encapsulation efficiency (EE), loading capacity (LC), particle size, polydispersity index (PDI), zeta potential, and stability, were systematically characterized. The in vitro anti-tumor activity was evaluated using cellular uptake, apoptosis assays, reactive oxygen species (ROS) detection, and a cell scratch test in HeLa and C33a cells. The in vivo therapeutic efficacy was verified using a nude mouse xenograft model of cervical cancer combined with histopathological analysis. Results: Microfluidic preparation yielded PSA-DOX/ICG-Lip with favorable physicochemical properties: the EE and LC of DOX were 96.52 ± 0.43% and 8.70 ± 0.04%, respectively, while those of ICG were 90.72 ± 1.10% and 0.82 ± 0.02%. The average particle size was 92.68 ± 1.14 nm with a PDI of 0.04 and a zeta potential of −9.66 ± 0.46 mV. The liposomes maintained good stability in terms of EE, particle size, PDI, and zeta potential after 28 days of storage at 4 °C and room temperature, with PSA modification significantly reducing the drug leakage rate. In vitro drug release studies showed that 808 nm laser irradiation triggered a significant increase in drug release from the liposomes. ICG encapsulated in liposomes mediated localized photothermal heating, and PSA targeting precisely confined the therapeutic effect to the tumor site, minimizing damage to adjacent normal tissues. In vitro experiments demonstrated that PSA-DOX/ICG-Lip, combined with laser irradiation, significantly enhanced cellular uptake, elevated intracellular ROS levels, inhibited cancer cell migration, and induced apoptosis. In vivo studies confirmed that this formulation markedly suppressed tumor growth in nude mice, with a tumor inhibition rate of 81.5%, and exhibited good biocompatibility without obvious organ toxicity. Conclusions: The microfluidically prepared PSA-DOX/ICG-Lip possesses high drug encapsulation efficiency, uniform particle size, good stability and sustained drug release properties. It can efficiently convert light energy into thermal energy, target neutrophils to enhance the affinity for cervical cancer cells, and exert a synergistic anti-tumor effect via the combination of chemotherapy and photothermal therapy, which provides a promising nanoplatform for the precise treatment of cervical cancer. Full article

Prostate cancer frequently progresses to lethal, drug-resistant castration-resistant prostate cancer (CRPC), where conventional therapies often fail due to intrinsic and acquired resistance mechanisms. This resistance creates a critical therapeutic impasse, leaving patients with limited options and poor prognoses. Immunotherapy has emerged as a promising strategy to harness the immune system against these treatment-refractory tumors, offering a potential avenue to overcome the immunosuppressive barriers that underlie CRPC drug resistance. This review synthesizes findings from a structured search of PubMed, Web of Science, and Embase (2020–2025), revealing significant clinical progress: 4 vaccine trials, 5 immune checkpoint inhibitor trials, 18 combination therapy trials (≥2 agents), and 6 targeted drug trials have been conducted. Preliminary efficacy was observed in novel approaches like bispecific antibodies (e.g., Xaluritamig achieving 59% PSA50 response), PSMA-CAR-T (P-PSMA-101), and oncolytic viruses (Ad5 PSA/MUC-1/brachyury). Basic research identified four targeted resistance mechanisms (e.g., AR-LLT1, Pygo2, and HnRNP L) and one nanoparticle-mediated triple-combination therapy (CM-AMS@AD NPs integrating photothermal, chemotherapy, and immunotherapy), which enhanced cytotoxic T-cell infiltration and suppressed CRPC growth preclinically. These collective findings suggest the potential of immunotherapy for CRPC in overcoming resistance barriers and improving patient outcomes, with bispecific T cell engagers (Xaluritamig, 59% PSA50) and PSMA-directed CAR-T therapy (P-PSMA-101, >50% PSA reduction) emerging as the most promising near-term candidates and biomarker-stratified combinations (nivolumab plus rucaparib, 84.6% PSA50, in HRR-deficient patients) illustrating the transformative power of precision patient selection; however, these findings require validation in larger, biomarker-stratified trials before definitive conclusions can be drawn. Translating this potential into clinical reality requires optimized patient selection through predictive biomarkers and rigorously validated Phase III trials to confirm durable clinical responses and long-term survival benefits. Full article

Background: The development of plasmonic photothermal therapy (PPTT) to trigger cancer cells is often hindered by uncontrolled overheating and the lack of real-time feedback. Methods: In this study, we report the synthesis of gold nanorod-embedded mesoporous silica nanoshells (AuNR@Si) as a multifunctional theranostic platform designed for controlled hyperthermia and surface-enhanced Raman spectroscopy (SERS) monitoring. Using a layer-by-layer templating strategy, AuNRs were successfully obtained within a hollow silica architecture. Results: While AuNRs alone exhibited rapid photothermal spikes reaching 64 °C, the AuNR@Si platform moderated the photothermal response, maintaining a stable therapeutic window (41–45 °C). In vitro assays using T47D breast cancer cells demonstrated a 33% reduction in viability following irradiation. Furthermore, the structural stability of the AuNR@Si platform enabled SERS monitoring of cellular damage, identifying specific biochemical fingerprints of protein denaturation, cytochrome c release and DNA fragmentation. Conclusions: These results suggest that AuNR@Si nanoshells provide a safer, regulated approach to photothermal ablation with the added benefit of molecular detection, demonstrating proof-of-concept theranostic functionality in a luminal breast cancer model. Full article

Photothermal therapy (PTT) is an emerging non-invasive treatment for cancer, offering targeted, localized therapy with minimal side effects. Its growing significance lies in its ability to precisely heat and destroy tumor cells while sparing surrounding healthy tissue. This study aimed to validate the $\delta P1$ approximation for simulating light propagation and thermal effects in biological tissues, particularly for photothermal therapy (PTT) applications. The model is applied to various scenarios, including homogeneous and heterogeneous tissue geometries with different optical properties and nanoparticle concentrations. The results are compared with analytical solutions, Monte Carlo results and experimental data to assess model accuracy. The $\delta P1$ approximation demonstrates superior performance compared to Beer–Lambert and Standard diffusion models, accurately predicting temperature distributions and capturing the influence of heterogeneous geometries. These findings highlight the potential of the $\delta P1$ model to significantly advance the field of PTT by providing reliable predictions for treatment planning and optimization. Full article

Targeting the Warburg effect (aerobic glycolysis) in tumor cells represents a promising metabolic therapeutic strategy in cancer research. This review analyzes the regulatory mechanisms and therapeutic potential of key glycolysis pathway components, including glucose transporters (GLUTs) and glycolytic enzymes such as hexokinase 2 (HK2), phosphofructokinase (PFK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), pyruvate kinase M2 (PKM2), and lactate dehydrogenase A (LDHA). We evaluate the molecular mechanisms of various inhibitors and the current clinical development landscape, noting that limitations of monotherapy stem not only from tumor metabolic plasticity but also largely from the unacceptable toxicity of many inhibitors due to the essential role of glycolysis in normal cell metabolism. Furthermore, we explore the molecular basis of synergistic interactions between glycolysis inhibitors and chemotherapy, radiotherapy, immunotherapy, photothermal therapy, and targeted therapy, proposing that rational combination strategies may help overcome resistance and improve therapeutic efficacy. Finally, the review outlines future challenges and directions, emphasizing that the primary obstacle in metabolic treatments is achieving selective inhibition of glycolytic enzymes in cancer cells while sparing normal cells. To address this challenge, the development of high-selectivity agents, cancer-specific nanodelivery systems, precise biomarker identification, and innovative combination regimens based on metabolic-immune regulation is crucial for advancing glycolysis-targeted therapy toward clinical translation. Full article